Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccinesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval Ad26.COV2-S Administered Admission adverse event adverse events age analyzed anti-SARS-CoV-2 vaccine BNT162b2 calculated Campylobacter jejuni ChAdOx1 collected CoronaVac COVID-19 diarrhea died dose doses epidemiological Guillain-barrè syndrome immunization inactivated incidence interquartile range Intravenous immunoglobulin male median Mild mRNA-1273 mRNA-based Patient performed plasma positive provided recipient reported risk SARS-CoV-2 Seven Surveillance survivor symptom onset syndrome tested treated vaccination Vaccine Vaccines variant [DOI] 10.1111/ene.15504 PMC 바로가기
Comparison of SARS-CoV-2 spike antibody quantitative titer reporting using the World Health Organization International Standard Units by four commercial assaysArticle Published on 2022-11-012022-11-15 Journal: Journal of Clinical Virology [Category] SARS, 진단, [키워드] Abbott Accuracy antibodies antibody Antibody Response Antibody titer Architect BAU BNT162b2 ChAdOx1-S collected comparable correlation COVID-19 DiaSorin effective Elecsy elicited Genscript greater IgG immune response Immunoglobulin indicated individual International LIAISON Moderna mRNA-1273 naïve Neutralizing antibody titer Oxford-AstraZeneca Pfizer/BioNTech plasma protective immunity Quantitative Quantitative serological assays ranged regression analysis response Roche SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination sensitivity seroconverted serological serological response significantly higher specificity Standard tested the WHO unit Vaccine Vaccines virus neutralization assays WHO WHO International Standard World Health Organization [DOI] 10.1016/j.jcv.2022.105292 PMC 바로가기
Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccinationArticle Published on 2022-11-012022-11-15 Journal: European journal of haematology [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome Adults antibody Antibody Response approved BNT162b2 Cell clinically Combination coronavirus disorder dose Efficacy FDA healthy Hospitalization IgG levels increased mortality Lymphocytes majority mRNA mRNA vaccination mRNA vaccine mRNA-1273 Multiple myeloma NAb NAbs Patient plasma Plasma cell disorder Prospective Study required responses SARS CoV-2 SARS-CoV-2 therapy Treatment vaccination vaccine dose [DOI] 10.1111/ejh.13826 PMC 바로가기
An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)Article Published on 2022-11-012022-11-15 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 진단, [키워드] age anti-RBD antibody B cell response BNT162b2 booster Cell-mediated immunity ChAdOx1 ChAdOx1 nCoV-19 comparable Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose elicit group humoral immunization Immunocompromised immunogenicity investigated IQR kidney transplant male median mononuclear cells mRNA mRNA-1273 no difference participant Peripheral blood positive Randomized Randomized controlled trial receive recipients response SARS-CoV-2 seroconversion rate significantly statistically T cell Vaccine Viral vector virus neutralization test [DOI] 10.1111/ajt.17151 PMC 바로가기
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort studyArticle Published on 2022-10-272022-11-15 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI Ad26.COV2.S Ad26.COV2.S vaccine age Analysis anti-SARS-CoV-2 Anti-spike antibody Antibody Response Antiretroviral therapy approved assays BNT162b2 CD4+ T-cell CD8+ T-cell ChAdOx1-S comparable Concentration conducted Control controls COVID-19 defined ELISPOT Endpoint Environment Final generally mild geometric HIV HIV-negative IFN-γ immunogenic immunogenicity Increased IQR less maintain male marker median age mRNA vaccination mRNA vaccine mRNA-1273 mRNA-based vaccines Netherland Netherlands of BNT162b2 PLWH predicted primary endpoint prospective cohort study Public reactogenicity receiving recipients reduced Registered remained required response SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 spike peptide SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Serious Adverse Events serological response Sex suppressed T-cell Response the median the vaccine Trial vaccination Vaccine vaccine group Viral load with HIV [DOI] 10.1371/journal.pmed.1003979 PMC 바로가기
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 VariantsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome antibody AZD1222 booster vaccination cellular Cellular immune response cellular immune responses cellular immunity coronavirus COVID-19 Delta delta variant dose effective elevated elicit Emergency use authorization emerging variants evaluated Evidence Heterologous heterologous prime-boost heterologous vaccination humoral immune immune evasion immune response immune responses IMPROVE increase in induce Infection interferon mRNA mRNA vaccine mRNA-1273 Multiple Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody omicron Prevent priming promote Protein subunit protein subunit vaccine provided RBD Receptor binding domain reduced regimen response SARS-CoV-2 SARS-CoV-2 variants significantly subunit suggested T cell Taiwan vaccination vaccination schedule Vaccine variant variants Viral variants wild type [DOI] 10.1128/spectrum.00609-22 PMC 바로가기
Detection of SARS-CoV-2 Neutralizing Antibodies in Vaccinated Pregnant Women and Neonates by Using a Lateral Flow Immunoassay Coupled with a Spectrum-Based ReaderArticle Published on 2022-10-182022-11-15 Journal: Biosensors [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료제, [키워드] antibody Better Blood booster collected Concentration correlation COVID-19 COVID-19 vaccine cut-off value Delta-type SARS-CoV-2 demonstrated detection ELISA enrolled enzyme-linked immunosorbent assay examined Flow greater IgG IgG level Lateral lateral flow lateral flow immunoassay Moderna mother mRNA-1273 Neonate Neutralizing Neutralizing antibodies neutralizing antibody Omicron-type SARS-CoV-2 Pregnancy pregnant women Receptor binding domain S1RBD IgG SARS-CoV-2 serum single dose Spike protein vaccination Vaccine wild-type SARS-CoV-2 wild-type SARS-CoV-2. [DOI] 10.3390/bios12100891 PMC 바로가기
Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA VaccinationArticle Published on 2022-10-172022-11-15 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] activity acute respiratory syndrome Against BNT162b2 convalescent convalescent patient coronavirus coronavirus disease COVID-19 cross-neutralizing cross-neutralizing antibody dose evaluated induce mRNA mRNA vaccination mRNA-1273 Neutralizing antibody titer omicron Received SARS-CoV-2 SARS-CoV-2 variants second vaccination seropositive severity subject the disease variant [DOI] 10.1093/infdis/jiac178 PMC 바로가기
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infectionArticle Published on 2022-10-172022-11-15 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 진단, [키워드] assays BNT162b2 BNT162b2 vaccine class correlated demonstrated develop dose doses epitope exhibited Frequency greater healthcare worker healthy IFN-γ IgG response IL-2 IL2 Immunity individual infected with SARS-CoV-2 Infection Interferon-gamma interleukin-2 magnitude Moderna mRNA-1273 vaccine mononuclear cell mRNA-1273 N and M nine participant Participants PCR testing peptide Peripheral blood Pfizer-BioNTech positive Post-infection Proteins proteome repeated responders response responses against robust S glycoprotein S1 and S2 S2 subunit SARS-CoV-2 SARS-COV-2 infection structural protein subunit subunits T cell response T-cell Response the SARS-CoV-2 uninfected vaccination vaccinee was determined were expressed with COVID-19 [DOI] 10.1371/journal.pone.0276241 PMC 바로가기
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesArticle Published on 2022-10-152022-11-16 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted age analyses Analysis aRR association B.1.1.529 benefit BNT162b2 booster booster dose Booster vaccine calculated ChAdOx1 nCoV-19 Chronic kidney disease Committee Comorbidities Comorbidity conducted core covariates COVID-19 COVID-19 hospitalisation COVID-19 infection COVID-19 therapeutics COVID-19 vaccination current death dominant Edinburgh England event group Health health condition high risk hospitalisation identify immunisation Immunosuppressant increased risk individual initial Innovation Ireland male Medical Research Council meta-analyses Moderna mortality data mRNA-1273 Multimorbidity National of BNT162b2 offer older adult outcome outcomes Oxford-AstraZeneca per 1000 person-year per 1000 person-years Pfizer-BioNTech Poisson regression model primary care prospective cohort prospective cohort study rate ratio receiving reduced reduced risk remained risk risk factor RT-PCR testing SARS-COV-2 infection Scottish severe COVID-19 Sex those with comorbidity university vaccination Vaccine vaccine dose vaccine group variant [DOI] 10.1016/S0140-6736(22)01656-7 PMC 바로가기